查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年北美傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路
市場調查報告書
商品編碼
1562248

2030 年北美傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路

North America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 100 Pages | 訂單完成後即時交付

價格

2022年北美傳染病治療市值為463.7653億美元，預計到2030年將達到659.5597億美元；預計2022年至2030年複合年成長率為4.5%。

傳染病發生率上升推動北美傳染病治療市場

傳染病是由病毒、寄生蟲、細菌、真菌、有毒產物和其他傳染源引起的。愛滋病毒是全世界的重大公共衛生議題。根據聯合國愛滋病毒/愛滋病聯合規劃署 (UNAIDS) 的數據，2020 年，約有 3,770 萬人感染愛滋病毒。其中，3600萬是成年人，170萬是0-14歲的兒童。此外，超過一半（53%）是女孩和婦女。此外，2020 年全球報告了 150 萬新的愛滋病毒病例。同樣，肝炎是由病毒感染引起的肝臟感染。肝炎病毒的主要類型為甲型、乙型、丙型、丁型和戊型 根據世界衛生組織(WHO) 統計，全球約有5,800 萬人患有慢性丙型肝炎病毒感染，每年約有150 萬人患有慢性丙型肝炎病毒感染。

據世界衛生組織稱，結核病 (TB) 是全球第 13 大死亡原因，也是僅次於 COVID-19 的第二大傳染病。 2020 年，結核病導致 150 萬人死亡（其中 214,000 人感染愛滋病毒）。此外，2020年全球有1,000萬人患有結核病，其中包括110萬名兒童、330萬名女性和560萬男性。此外，院內感染或醫療保健相關感染（HAI）的發生率和死亡率很高。此外，每年醫療保健系統的支出也是巨大的。美國疾病管制與預防中心 (CDC) 報告稱，醫院感染每年在美國醫院造成約 170 萬例感染病例和 99,000 例死亡。因此，全球傳染病率的上升推動了傳染病治療市場的成長。

北美傳染病治療市場概況

北美的傳染病治療市場分為美國、加拿大和墨西哥。到 2022 年，北美將佔據全球市場的最大佔有率。此外，大型醫療保健企業以及對治療慢性病和病毒性疾病的先進治療解決方案不斷成長的需求正在推動該地區的市場擴張。由於抗病毒療法的日益採用，對抗病毒藥物的需求不斷成長，預計將推動美國市場的發展。主要醫藥和生物製藥公司致力於擴大其抗病毒藥物的生產能力。例如，加州吉利德科學公司(Gilead Sciences, Inc.) 於2020 年5 月獲得FDA 批准用於治療COVID-19 的研究性抗病毒藥物瑞德西韋(Remdesivir)。管理局(FDA) 於2022 年4 月批准了一種補充新藥吉利德科學公司的Veklury（瑞德西韋）申請（sNDA）用於治療年齡超過28 天、體重至少3 公斤、因COVID-19 住院治療或患有輕度至中度COVID-19 感染的兒科患者。 2021 年 9 月，拜登-哈里斯政府透過疾病管制與預防中心 (CDC) 投資 21 億美元，以改善全國公共衛生和醫療保健部門的感染控制和預防活動。預計這些因素將在預測期內推動美國傳染病治療市場的成長。

北美傳染病治療市場收入及 2030 年預測（百萬美元）

北美傳染病治療市場細分

北美傳染病治療市場按藥物類別、適應症、給藥途徑、配銷通路和國家分類。

依藥物類別，北美傳染病治療市場分為抗病毒、抗菌、抗真菌等。 2022 年，抗病毒藥物領域佔據最大的市場佔有率。

從適應症來看，北美傳染病治療市場分為愛滋病毒、肝炎、結核病、流感、HPV等。 2022 年，HIV 佔據最大的市場佔有率。

依給藥途徑，北美傳染病治療市場分為口服、腸胃外、外用等。 2022 年，口腔細分市場佔據最大的市場佔有率。

從配銷通路來看，北美傳染病治療市場分為醫院藥局、零售藥局等。 2022年，醫院藥局佔最大的市場佔有率。

依國家/地區分類，北美傳染病治療市場分為美國、加拿大和墨西哥。 2022年，美國在北美傳染病治療市場佔有率中佔據主導地位。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc 和 Shionogi & Co Ltd 是在北美傳染病治療市場。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美傳染病治療市場 - 主要市場動態

  • 北美傳染病治療市場 - 主要市場動態
  • 市場促進因素
    • 傳染病病率上升
    • 越來越關注傳染病治療的經費與研發
  • 市場限制
    • 抗感染藥物抗藥性的出現及相關副作用
  • 市場機會
    • 發展中國家不斷成長的機會
    • 抗生素抗藥性威脅不斷升級
  • 未來趨勢
    • 產品批准和發布數量不斷增加
  • 促進因素和限制的影響：

第 5 章：傳染病治療市場 - 北美市場分析

  • 北美傳染病治療市場收入，2022-2030

第 6 章：北美傳染病治療市場分析 - 按藥物類別

  • 概述
  • 抗病毒劑
  • 抗菌
  • 抗真菌
  • 其他

第 7 章：北美傳染病治療市場分析 - 按適應症

  • 概述
  • 愛滋病
  • 肝炎
  • 結核
  • 流感
  • HPV病毒
  • 其他

第 8 章：北美傳染病治療市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 專題
  • 其他

第 9 章：北美傳染病治療市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：北美傳染病治療市場 - 國家分析

  • 美國
  • 加拿大
  • 墨西哥

第 11 章：傳染病治療市場-產業格局

  • 概述
  • 傳染病治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附錄

Product Code: BMIRE00030503

The North America infectious disease therapeutics market was valued at US$ 46,376.53 million in 2022 and is expected to reach US$ 65,955.97 million by 2030; it is estimated to register a CAGR of 4.5% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels North America Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

North America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US. Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection. In September 2021, the Biden-Harris Administration invested US$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.

North America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Infectious Disease Therapeutics Market Segmentation

The North America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the North America infectious disease therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the North America infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - North America Market Analysis

  • 5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 North America Infectious Disease Therapeutics Market Overview
    • 10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 BioCryst Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 GSK Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AbbVie Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Merck & Co Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Astellas Pharma Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. North America Infectious Disease Therapeutics Market Segmentation
  • Table 2. Diseases and Funding
  • Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market